When patients aged 50 years old start triple therapy, event-free survival was estimated to increase by 3.2 years (95% CI 2.14.3 years) for MACE, 3.2 years (95% CI 2.44.0 years) for HHF, and 5.5 years (95% CI 4.06.7 years) for CKD progression compared with that for conventional therapy alone
For Tesofensine, the focus is squarely on powerful appetite suppression and subsequent weight loss, with secondary interests in neurological pathways related to food reward and mood
10.1208/s12248-008-9078-8 155 SinghN.ParasharP.TripathiC
paradoxically, certain gut-derived metabolites may help limit post-stroke inflammation and support neurorepair (Hu et al., 2022)
They do not imply therapeutic, diagnostic, or clinical benefit
TER measurements Resistance of the urothelial multilayers was assessed by TER measurement using an epithelial volt-ohm metre (World Precision Instruments)